PharmTech Drug Digest 11.20
|Articles|October 23, 2009

Uniting all CROs

US-based CRO, Health Decisions, hopes to raise the efficacy standards for complex studies and help companies get products to market faster by establishing an international network of CROs.

US-based CRO, Health Decisions, hopes to raise the efficacy standards for complex studies and help companies get products to market faster by establishing an international network of CROs.

"It's no surprise that, as development moves overseas, disparate systems and gaps in information inevitably drive up costs and prolong development timelines," Rick Farris, Health Decisions Chief Operations Officer, explained in a press statement. "This network will serve as an incredibly valuable resource to combat inefficiency in global clinical trials."

In the statement, Health Decisions claims that its proprietary Agile approach to clinical research forms "a set of best practices that consistently cuts trial timelines, increases transparency and delivers vastly improved results". The CRO has identified like-minded CROs worldwide and will be offering training, certification and partnership opportunities. Farris said: "Regardless of what they call it — Agile clinical development or otherwise — if they're comfortable with adaptive techniques in both design and operations, and pride themselves on relentless efficiency in clinical research, we want to talk to them."

The company's training programme, which will comprise Flash-based online courses, will primarily focus on adaptive operations that are easy to implement for all types of trials once the proper infrastructure is in place.

Farris added: "Our goal is to identify like-minded organizations worldwide that embrace the idea that we, as an industry, can run better global studies."

www.healthdec.com

A webcast from Health Decisions can be viewed here.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.